HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.37; value investors ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Shares of NASDAQ HALO opened at $57.10 on Friday. The company has a debt-to-equity ratio of 3.32 ...

In the preceding three months, 8 analysts have released ratings for Halozyme Therapeutics (NASDAQ:HALO), presenting a wide ... Therapeutics's financials over 3 months reveals a positive narrative.

Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the 4th ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report ... for Halozyme Therapeutics’ current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Halozyme ...

3 Stocks to DOUBLE This Year The 10 Best Stocks ... of “Moderate Buy” and a consensus price target of $60.89. NASDAQ:HALO opened at $56.28 on Tuesday. The firm has a fifty day simple moving ...

The subcutaneous formulation of Rybrevant, also known as amivantamab, was developed using Halozyme's (NASDAQ:HALO) Enhanze drug delivery technology.

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this Medical stock. HALO has a Momentum Style Score of A, and shares are up 15.9% over the past ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year ...